Seqitope® allows us to compare large panels of antibodies in parallel and characterize their molecular binding profiles at high resolution. By analyzing multiple TROP2 binders side by side, we hope to better understand the molecular characteristics associated with different therapeutic properties.

Through this collaboration with AAX Biotech, Seqitope® will allow us to elucidate at the molecular level what sets our antibodies apart, an insight that is essential as we advance them towards therapeutic application.

Integrating Opti-mAb® early in the antibody discovery and development process allows us to address key challenges already at the design stage and support the selection of more developable antibody candidates. Through our partnership with evitria, a trusted provider of antibody engineering and expression services, we can extend the use of Opti-mAb® across a wider range of antibody discovery programs.

evitria works with companies at the earliest stages of antibody discovery where time is limited and risk is high. By offering our customers access to AAX’s Opti-mAb® technology, we strengthen our ability to deliver complex antibody formats and support our customers in selecting high-quality molecules with improved stability and expression. This partnership with AAX Biotech reflects our commitment to continuously expand our scientific capabilities and deliver added value to our customers.

This investment marks the next phase of platform development and expansion. With Trio Impact Invest’s support, we can scale our proprietary platforms, broaden their impact across antibody discovery and development, and strengthen collaborations with new and existing partners.

The ability to generate high-resolution epitope data at true high throughput represents a significant advance for antibody discovery and development. With Seqitope® and our new robotic platform, we can now characterize up to 100 antibodies in parallel, providing Vascurie with rapid, high-quality insights to support their neuro-oncology programs.

This collaboration strategically accelerates our initiative to develop monoclonal antibodies targeting CD93. The dataset generated together with AAX Biotech will allow Vascurie to de-risk the development and optimize the selection of backup compounds.

This project represents an exciting new application of Seqitope® beyond its established use in antibody epitope mapping. With our cutting-edge technologies to advance biologic drug discovery, we are pleased to collaborate with ToxoTech and leverage Seqitope® to guide rational design and accelerate the development of precision-engineered biologics.

At ToxoTech, we bring extensive experience in the drug design of biotherapeutics for neurology, and we see Seqitope® as a valuable complement to our discovery pipeline. Working together with AAX Biotech allows us to accelerate the development of innovative therapies with the potential to transform treatment options across neurological and neuromuscular indications.

For AAX Biotech, collaborating with a company with the scale and reputation of Daiichi Sankyo represents a tremendous validation of our innovative approach. This provides us with the opportunity to showcase the power of Opti-mAb® in collaboration with a truly global leader in pharmaceutical innovation. We are excited to work closely with the world-class scientific teams at Daiichi Sankyo.

We are pleased to support our partner in this important phase of their drug candidate’s clinical development. With Seqitope®, we provide the precision needed to optimize antibody characterization, and we look forward to supporting their continued progress.

We’re seeing strong and growing interest in our Seqitope® and Opti-mAb® platforms, which is driving momentum for the company. Strengthening both our R&D and commercial teams is a natural next step, and I’m very pleased to welcome Ionut and Kushal to AAX Biotech.

We are pleased to see strong support from many of our existing investors, with some increasing their commitment substantially, demonstrating strong confidence in our mission and the value of our technologies. We’re also excited to welcome new investors on board. With these resources, we are positioned to deliver innovative solutions that address some of the most critical medical challenges.

Patrik Strömberg's comprehensive knowledge in both scientific and business aspects of the pharmaceutical industry makes him an invaluable addition to the board. His insights and leadership will be instrumental in accelerating our growth, enhancing our technological capabilities and solidifying our position in the global market.

Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide. We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.

Being awarded the AbbVie Scandinavia Golden Ticket is a tremendous honor and validation of our innovative approach to biotechnology. This recognition not only fuels our commitment to pushing the boundaries of biotech but also significantly accelerates our mission to meet the unmet medical needs of today. We are eager to leverage this opportunity to enhance patient treatment methods and improve quality of life.

The addition of Juan to our team represents a key milestone for AAX. His combination of technical know-how and forward-thinking leadership is set to elevate our technologies to new heights of innovation and market success. Juan's contribution is essential as we strive for scientific excellence and leadership in the bioanalytical market.

These appointments mark a significant milestone for AAX Biotech and are anticipated to play a vital role in the company’s growth and the development of our cutting-edge technologies, Seqitope™ and Opti-mAb™. We believe that the diverse expertise of our new board members will drive innovation and enhance our strategic initiatives in the evolving biotech landscape.

We are thrilled to join forces with Oblique Therapeutics and contribute our powerful Seqitope™ technology to their drug development efforts. Our high-resolution, high-throughput method will empower Oblique Therapeutics to expedite their development process and bring novel therapeutics to the market faster.

We are thrilled to have Maria join the team as we strengthen our IP portfolio and build partnerships with biotech and pharma companies. Maria’s combined experience in antibody research and business development will be instrumental for advancing AAX Biotech’s cutting-edge technologies for antibody therapeutics.